Welcome to our dedicated page for Immunocore Holdings Plc news (Ticker: IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings Plc stock.
Immunocore Holdings Plc (IMCR) delivers pioneering T cell receptor therapies through its ImmTAX platform, targeting complex diseases in oncology and immunology. This dedicated news hub provides investors and industry observers with essential updates on the company's scientific advancements and corporate developments.
Access authoritative reporting on clinical trial progress, regulatory milestones, and strategic partnerships shaping Immunocore's position in biotherapeutics. The curated collection includes verified press releases covering drug candidate evaluations, financial disclosures, and technology innovations like the KIMMTRAK therapy for metastatic uveal melanoma.
Key content categories include updates on immuno-oncology research, infectious disease programs, and autoimmune treatment pipelines. Users will find analysis-neutral reporting on FDA interactions, collaborative research initiatives, and quarterly performance metrics essential for informed decision-making.
Bookmark this page for streamlined access to Immunocore's latest verified developments. Check regularly for real-time updates on groundbreaking TCR-based therapies and their impact on global healthcare solutions.
Resolution Therapeutics has strengthened its leadership team with two key appointments: Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer. The appointments follow the successful dosing of the first patient in the company's Phase I/II EMERALD study.
Lucy Singah brings over 20 years of corporate and strategic finance experience from companies including Echopoint Medical, GSK, and EY. Daniel Kennedy, with more than 20 years of business development experience, joins from Immunocore (NASDAQ: IMCR) and previously led deals at Achillion Pharmaceuticals, including its $930 million acquisition by Alexion.
The company will host an R&D Webinar on September 17, 2025, featuring clinical hepatologists to discuss its regenerative macrophage therapy (RMT) platform for inflammatory and fibrotic diseases.
Immunocore (NASDAQ: IMCR), a commercial-stage biotechnology company, has announced its participation in four major investor conferences in September 2025. The company will participate in the Cantor Global Healthcare Conference (Sept 5), H.C. Wainwright Global Investment Conference (Sept 8), Baird Global Healthcare Conference (Sept 9), and Morgan Stanley Global Healthcare Conference (Sept 10).
Immunocore specializes in developing novel TCR bispecific immunotherapies (ImmTAX) for cancer, autoimmune, and infectious diseases. Their flagship product, KIMMTRAK, is approved in multiple regions for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Immunocore (NASDAQ:IMCR) reported strong Q2 2025 financial results, with KIMMTRAK net revenues reaching $98.0 million, representing a 30% year-over-year growth. The company achieved significant market expansion with KIMMTRAK now approved in 39 countries and launched in 28 countries globally.
Key highlights include 15% growth in US sales and 71% growth in Europe and international regions. The company maintains a strong financial position with $883 million in cash and equivalents. R&D expenses increased to $69.0 million, reflecting investments in autoimmune programs and Phase 3 trials.
Clinical progress remains on track with the Phase 3 TEBE-AM trial expected to complete enrollment in 1H 2026, and dose selection for PRISM-MEL-301 Phase 3 trial anticipated in 2H 2025. The company reported a reduced net loss of $10.3 million compared to $11.6 million in the same period last year.
Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company, will release its second quarter 2025 financial results on Thursday, August 7, 2025, before US markets open. The company will host a conference call and webcast at 8:00 a.m. EDT to discuss results and provide business updates.
Immunocore specializes in developing novel TCR bispecific immunotherapies (ImmTAX) for cancer, autoimmune, and infectious diseases. Their lead product, KIMMTRAK, is approved in multiple regions for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Immunocore (NASDAQ: IMCR) has presented initial data from the multiple ascending dose (MAD) portion of its Phase 1/2 STRIVE trial for IMC-M113V, a functional HIV cure candidate. The study included 16 HIV-positive participants across three dose cohorts (60 mcg, 120 mcg, and 300 mcg).
Key findings show that IMC-M113V was well-tolerated with no serious adverse events. The 300 mcg cohort showed promising results, with 2 out of 5 patients demonstrating viral control. Notably, these patients maintained viral loads around 200 c/mL at week 8, significantly better than the historical rate of 5%.
The trial revealed dose-dependent viral control after antiretroviral treatment interruption, with some patients showing reduced CD4+ T cell-associated HIV Gag RNA, indicating a reduction in active virus reservoir. Two patients remained off antiretroviral treatment for the entire 12-week interruption period, with one patient showing viral reduction to <50 c/mL at week 12 - an outcome typically seen in <1% of cases.
Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, has announced its participation in three major investor conferences in March 2025.
The company will be present at:
- The TD Cowen 45th Annual Healthcare Conference with a presentation on Tuesday, March 4, 2025, at 3:10 p.m. EST
- The Barclays 27th Annual Global Healthcare Conference for a fireside chat on Tuesday, March 11, 2025, at 3:00 p.m. EST
- The Jefferies Biotech on the Beach Summit for one-on-one and small group meetings on Wednesday, March 12, 2025
Interested parties can access live webcasts of the presentations through the 'Events & Presentations' section under 'Events' in the 'Investors' area of Immunocore's website. Replay options will be available for a time after the events.
Immunocore (NASDAQ: IMCR) reported Q4 2024 financial results with KIMMTRAK net sales of $84.1M and full-year sales of $310.0M. The company achieved 11 consecutive quarters of revenue growth and expanded to 14 new territories.
Q4 net loss was $23.8M ($0.47 per share) compared to $19.7M in Q4 2023. Full-year 2024 net loss was $51.1M ($1.02 per share) versus $55.3M in 2023. R&D expenses increased to $222.2M from $163.5M in 2023.
Key developments include:
- KIMMTRAK now approved in 39 countries and launched in 24
- First patient randomized in Phase 3 PRISM-MEL-301 trial
- Initiated Phase 1/2 trial of IMC-R117C for colorectal cancers
- Strong cash position of $820.4M as of December 31, 2024
- Repaid $50M Pharmakon loan in November 2024
Immunocore Holdings (Nasdaq: IMCR), a commercial-stage biotechnology company focused on immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, has announced it will release its fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025.
The company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss the financial results and provide updates on its business and portfolio. The webcast will be accessible through the 'Events' section of Immunocore's website, with a replay available for a time afterward.
FAQ
What is the current stock price of Immunocore Holdings Plc (IMCR)?
What is the market cap of Immunocore Holdings Plc (IMCR)?
